Inhibition of the acetyltransferase NAT10 normalizes progeric and aging cells by rebalancing the Transportin-1 nuclear import pathway. by Larrieu, Delphine et al.
1	
Inhibition of the acetyltransferase NAT10 normalizes progeric and aging cells by 
rebalancing the Transportin-1 nuclear import pathway  
 
Authors: Delphine Larrieu1,2*, Emmanuelle Viré1,3Y, Samuel Robson1,4Y, Sophia Y. 
Breusegem2, Tony Kouzarides1 and Stephen P. Jackson1* 
 
Affiliations: 
1 The Wellcome Trust/Cancer Research UK Gurdon Institute and Department of 
Biochemistry, University of Cambridge, CB2 1QN, United Kingdom. 
2 Current address: Cambridge Institute for Medical Research, Department of clinical 
biochemistry, University of Cambridge, CB2 0XY, United Kingdom 
3 Current address: MRC Prion Unit at UCL, Institute of Prion Diseases, Queen Square House, 
Queen Square London, WC1N 3BG, United Kingdom  
4 Current address: School of Pharmacy & Biomedical Science, University of Portsmouth, 
PO1 2UP, United Kingdom 
* Corresponding authors. Email: dl437@cam.ac.uk or s.jackson@gurdon.cam.ac.uk 
Y These authors contributed equally to the work. 
 
  
2	
ABSTRACT 
Hutchinson-Gilford progeria syndrome (HGPS) is an incurable premature ageing disease. 
Identifying deregulated biological processes in HGPS might thus help define novel 
therapeutic strategies. Fibroblasts from HGPS patients display defects in nucleo-cytoplasmic 
shuttling of the GTP-bound form of the small GTPase Ran (RanGTP), which leads to 
abnormal transport of proteins into the nucleus. Here, we report that microtubule stabilisation 
in HGPS cells sequestered the non-classic nuclear import protein Transportin-1 (TNPO1) in 
the cytoplasm, thus affecting the nuclear localisation of its cargos, including the nuclear pore 
protein NUP153. Consequently, nuclear Ran, nuclear anchorage of the nucleoporin TPR, and 
chromatin organisation were disrupted, deregulating gene expression and inducing 
senescence. Inhibiting N-acetyltransferase 10 (NAT10) ameliorated HGPS phenotypes by 
rebalancing the nuclear to cytoplasmic ratio of TNPO1. This restored nuclear pore complex 
integrity and nuclear Ran localisation, thereby correcting HGPS cellular phenotypes. We 
observed a similar mechanism in cells from healthy aged individuals. This study identifies a 
nuclear import pathway affected in ageing and underscores the potential for NAT10 
inhibition as a possible therapeutic strategy for HGPS, and perhaps also for pathologies 
associated with normal ageing. 
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INTRODUCTION 
Hutchinson-Gilford progeria syndrome (HGPS) is a very rare, fatal premature ageing 
syndrome caused by a de novo heterozygous point mutation within exon 11 of the lamin A 
(LMNA) gene (1,2). LMNA encodes two type V intermediate filament proteins: lamin A and 
lamin C. Together with B-type lamins, these proteins form the nuclear lamina at the inner 
nuclear membrane, where they act as a scaffold to maintain nuclear architecture, nuclear pore 
complexes, and chromatin organisation, and to regulate DNA replication and transcription. In 
HGPS, the mutation only affects lamin A and causes the production of a truncated, toxic form 
of the protein called progerin that acts as a dominant negative. Accumulation of progerin at 
the inner nuclear membrane alters nuclear lamina structure, causing abnormal nuclear 
morphology, aggregation of nuclear pore complexes, chromatin disorganisation due to loss of 
peripheral heterochromatin anchorage, and transcriptional deregulation, all of which 
ultimately lead to DNA damage accumulation and premature entry of HGPS cells into 
senescence (3-6). These cellular phenotypes are also observed in cells from healthy aged 
individuals. In HGPS patients, progerin accumulation triggers segmental premature ageing, in 
which most tissues are affected but the patient displays only some of the phenotypes typical 
of normal aging, usually starting within the first year of life and leading to death at the 
average age of 14, mainly due to heart defects (7,8). Although HGPS syndrome was first 
described over a century ago, the exact mechanisms by which progerin drives such striking 
cellular and organismal phenotypes are still being explored.  
 
Various studies have reported disruption of nucleocytoplasmic transport in HGPS fibroblasts, 
due to an abnormal nucleocytoplasmic gradient of GTP-bound Ran (RanGTP) (9-11). Ran is 
a small GTPase that shuttles between the cytoplasm and the nucleus and cycles between 
GDP-bound and GTP-bound states (12), with conversion between these states being 
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catalysed by cytoplasmic factors, such as Ran GTPase-activating protein (RanGAP) (13), and 
nuclear factors, such as the regulator of chromatin condensation 1 (RCC1) (14,15). 
Therefore, Ran is predominantly in its GTP-bound form in the nucleus, and in its GDP-bound 
form in the cytoplasm. This creates a RanGTP gradient across the nuclear envelope (16,17), 
which allows active transport of protein cargoes through nuclear pore complexes by a family 
of carrier proteins called karyopherins. In HGPS, the presence of progerin induces defects in 
Ran nuclear localisation. Consequently, nuclear import of proteins requiring Ran-dependent 
active transport through nuclear pores appeared more strongly affected than that of proteins 
passively diffusing through nuclear pores in these cells. One of the proteins displaying 
reduced nuclear import in HGPS cells is the nucleoporin translocated promoter region (TPR) 
(9,10), a polypeptide of ~265 kDa that forms a homodimer and is thus one of the largest 
nucleoporins. TPR is the last protein recruited to the nuclear pore complex, and its anchorage 
in the nuclear envelope requires the nuclear pore protein NUP153 (18,19). We previously 
showed that disrupting NUP153 abundance or function affects Ran nuclear localisation, thus 
impairing nuclear import of p53-binding protein 1 (53BP1), which is involved in DNA 
damage repair. This contributes to DNA damage accumulation in ageing vascular smooth 
muscle cells (VSMCs) (20). Remodelin, a small-molecule inhibitor of N-acetyltransferase 10 
(NAT10) that normalises phenotypes of fibroblasts isolated from HGPS patients (21), 
restores NUP153 localisation and nuclear Ran in VSMCs through an uncharacterised 
mechanism (20). This raises the question of why the abundance of nuclear Ran is altered in 
HGPS cells and which aspect of nuclear transport machinery is disrupted, because NUP153 
can be imported by several import pathways (22-24). 
 
Here we show that the decrease of nuclear Ran abundance that occurs in cells from HGPS 
patients and in cells from aged individuals is linked to dysregulation of the non-classic 
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transport pathway mediated by Transportin-1 (TNPO1), also called karyopherin b2 (25). 
Unlike classical importin proteins, which are general transporters, TNPO1 only mediates the 
nuclear import of a subset of proteins. In the nucleus, RanGTP binds to TNPO1 to stimulate 
release of the cargo (26). Among TNPO1 cargos, the most extensively characterised is the 
RNA-binding protein heterogeneous nuclear ribonucleoprotein 1 hnRNPA1 (27), which 
functions in several processes including mRNA biogenesis and promotion of transcription 
factor activity (28-30). Nuclear pore complex protein NUP153 is also a target for TNPO1-
mediated nuclear import (24). Accordingly, we observed that hnRNPA1, NUP153, TPR, and 
nuclear Ran defects in HGPS cells were linked to deregulation of the TNPO1 nuclear-to-
cytoplasmic ratio. NAT10 inhibition restored the proper subcellular distribution of TNPO1 
and TNPO1-dependent nuclear import in HGPS cells, thereby promoting nuclear localisation 
of its cargos such as hnRNPA1 and NUP153. This allowed proper NUP153-dependent 
recruitment of TPR to the nuclear pore complex and restored chromatin reorganisation and 
global gene transcription, thus preventing premature entry of HGPS cells into senescence. 
NUP153 depletion did not affect the TNPO1 pathway, supporting the notion that TNPO1 
deregulation in HGPS is the cause and not the consequence of abnormal NUP153 nuclear 
localisation.  This study thus provides mechanistic insight into how NAT10 inhibition 
reverses HGPS cellular phenotypes and provides further evidence that it may also be relevant 
in normal ageing. 
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RESULTS 
Premature ageing and normal aged cells display nucleocytoplasmic transport defects 
We found by immunofluorescence staining that, as expected (31), most Ran was in the nuclei 
of interphase fibroblasts from a healthy 20-year-old individual (Fig. 1A). By contrast, and in 
line with previous reports (9,10), we observed that Ran localization was abnormal in 
fibroblasts from an HGPS patient (HGPS 11513), with most Ran being cytoplasmic (Fig. 
1A). Because evidence suggests that HGPS might recapitulate various aspects of normal 
ageing (32), we also looked at the subcellular localisation of Ran in fibroblasts from healthy 
individuals between 81 and 96 years-of-age (AG11240, AG04059, AG05248, and 
AG09602). Similarly to HGPS cells, nuclear Ran appeared to be depleted to various extents 
in cells from aged individuals (Fig. 1A). This reduction in nuclear Ran was not associated 
with an overall decrease in Ran abundance in fibroblasts from the HGPS patient or in 
fibroblasts from aged individuals (Fig. 1B), suggesting that changes in Ran subcellular 
localisation reflected dysregulated RanGTP gradient formation across the nuclear envelope 
rather than changes in Ran abundance. As reported previously (10), decreased nuclear Ran in 
HGPS cells was also associated with decreased nuclear staining intensity of the nucleoporin 
TPR (Fig. 1C, D) as well as in cells from aged healthy individuals (Fig. S1A, B). These 
results confirmed previous findings in HGPS cells and also suggested that a similar nucleo-
cytoplasmic transport defect may occur during normal ageing. 
 
Inhibition of NAT10 restores normal nucleocytoplasmic transport in HGPS cells 
Because the nuclear pore complex protein NUP153 is required to anchor TPR to the nuclear 
pore complex (18), we assessed whether NUP153 was present at the nuclear periphery by 
immunofluorescence in fibroblasts from control individuals and from HGPS patients 
(hereafter referred to as control or unaffected and HGPS fibroblasts, respectively). NUP153 
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nuclear intensity was significantly reduced in HGPS cells compared to controls, in a manner 
that correlated with decreased nuclear TPR staining (Fig. 1E, F and Fig. S2A). Because we 
had previously reported that inhibition of the N-acetyltransferase NAT10 reverses abnormal 
phenotypes of HGPS cells as well as aged smooth-muscle cells (20,21), we investigated 
whether NAT10 inhibition affected NUP153 and TPR staining. Indeed, when we treated 
HGPS cells with the NAT10 inhibitor Remodelin (21), this increased the nuclear staining 
intensity of NUP153 and TPR (Fig. 1E, F). To assess whether this reflected an enhanced 
interaction between the NUP153 and TPR proteins after Remodelin treatment, we performed 
a proximity ligation assay (PLA) (33) using primary antibodies recognizing TPR and 
NUP153. Whereas  NUP153 and TPR clearly interacted in control fibroblasts (Fig. 1G), the 
interaction was almost completely absent in untreated HGPS cells, in accord with these 
proteins being mislocalised. However, Remodelin treatment greatly enhanced the interaction 
between NUP153 and TPR in HGPS cells (Fig. 1G). This suggested that NAT10 inhibition 
promoted normal nuclear localisation and anchorage of both NUP153 and TPR at the nuclear 
periphery of HGPS cells. 
 
We next looked at the effect of NAT10 inhibition on Ran subcellular localisation in HGPS 
cells. Strikingly, short-interfering RNA (siRNA)-mediated depletion of NAT10, or NAT10 
inhibition by Remodelin nearly completely abolished Ran nuclear localisation defects in 
HGPS cells (Fig. 1H, I, Fig. S2B). In agreement with nuclear transport factor 2 (NTF2) 
mediating Ran nuclear import (34,35), siRNA depletion of NTF2 in control fibroblasts 
reduced Ran nuclear accumulation, similar to that observed in untreated HGPS cells (Fig. 1H, 
I). 
 
Reduction of nuclear Ran modifies chromatin compaction and triggers senescence 
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Because many cellular processes are disrupted in HGPS, we explored which might be 
associated with decreased nuclear Ran abundance. One of the phenotypes observed in HGPS 
cells is chromatin disorganisation and loss of heterochromatin marks, including 
trimethylation of histone H3 at lysine 9 (H3K9me3) (36,37). To assess whether disrupting 
Ran nuclear import could affect the state of chromatin at a global level, we transfected non-
progeric human bone osteosarcoma U2OS cells with siRNA targeting NTF2 (Fig. 2A) and 
looked at global chromatin compaction by treating nuclei harvested from these cells with 
micrococcal nuclease (MNase). The efficiency of MNase digestion varies with the degree of 
chromatin compaction. We used U2OS cells for this experiment instead of primary human 
cells because this assay requires a large number of cells. These assays established that 
disruption of nuclear Ran localisation led to global chromatin decompaction (Fig. 2B) and 
suggested that, by affecting the bi-directional transport of many large cargo proteins, Ran 
deregulation might have broad effects on chromatin organisation, as observed in HGPS 
(36,37). Chromatin relaxation was also observed – albeit to a lesser extent – upon TPR 
depletion, reflecting the known role of TPR and nuclear pore complexes in chromatin 
organisation at the nuclear periphery (38,39). 
 
We next assessed the effect of NTF2 depletion on the heterochromatin mark H3K9me3 in 
control and HGPS fibroblasts. We observed a marked decrease in H3K9me3 staining 
intensity upon NTF2 depletion in control fibroblasts (Fig. 2C, D), similar to the basal 
H3K9me3 staining observed in HGPS cells expressing a control siRNA. NTF2 depletion did 
not further reduce H3K9me3 in HGPS cells. Moreover, we observed a similar decrease in 
H3K9me3 in high-passage-number (P61) unaffected human fibroblasts, suggesting that the 
perturbation observed in HGPS cells resembles what happens when unaffected cells reach 
senescence. In addition to the effect on chromatin, disrupting nuclear Ran by depleting NTF2 
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also promoted the entry of control fibroblasts into senescence as measured by senescence-
associated β-galactosidase staining (Fig. 2E, F). However, depleting NTF2 in HGPS cells, 
which already had reduced nuclear Ran, did not significantly further increase the proportion 
of senescent cells. Collectively, these results suggested that the reduction in nuclear Ran 
observed in HGPS cells might, by globally affecting nucleocytoplasmic transport, contribute 
to downstream phenotypes of chromatin disorganisation and premature entry into senescence. 
 
NAT10 inhibition reverses TNPO1 nuclear import pathway defects in HGPS cells 
Neither the abundance nor the subcellular localisation of NTF2 appeared to be affected in 
HGPS cells (Fig. S3A), implying that defects in the Ran nuclear import machinery were not 
the cause of reduced nuclear accumulation of Ran in HGPS cells. Because NUP153 
disruption reduces the nuclear abundance of Ran (20), we hypothesized that Ran gradient 
deregulation occurring in HGPS might reflect the loss of NUP153 nuclear import. This led us 
to investigate which upstream pathway(s) could affect NUP153 nuclear import in HGPS 
cells. NUP153 can be imported by several proteins, but evidence suggests that NUP153 is 
imported into the nucleus of interphase cells by the non-classic nuclear transport receptor 
TNPO1 (24), a karyopherin β protein that promotes nuclear import of only a specific subset 
of proteins, including NUP153 and hnRNPA1. We therefore assessed TNPO1 subcellular 
localization in control and HGPS fibroblasts by immunofluorescence staining. Whereas 
TNPO-1 was nearly equally distributed between the cytoplasm and nucleus in unaffected 
fibroblasts, TNPO1 was depleted from the nucleus in HGPS cells (Fig. 3 A-B), similarly to 
what we had observed for Ran (Fig. 1). To determine whether changes in the nuclear-to-
cytoplasmic ratio of TNPO1 in HGPS cells had an impact on its nuclear importer function, 
we assessed the subcellular localization of hnRNPA1, one of the best-described TNPO1 
cargo proteins. In accord with TNPO1 pathway deficiency in HGPS cells, we observed a 
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marked decrease of nuclear hnRNPA1 in these cells (Fig. 3A). Similar defects were observed 
for the Ewing sarcoma protein (EWS), another characterised TNPO1 cargo (40) (Fig. S3B, 
C). In contrast, the localization of NAT10, the subcellular distribution of which is not 
detectably affected in HGPS (Fig. S4A and as described in (21)), was not altered upon 
interfering with TNPO1 function by expressing MBP-M9M, a peptide that binds to TNPO1 
and competes with its natural substrates (41) (Fig. S4B). These results identify the TNPO1 
nuclear import pathway as deregulated in HGPS. 
 
We also observed loss of nuclear TNPO1 in cells from unaffected aged individuals (Fig.  3C), 
with no apparent change in the abundance of TNPO1 or hnRNPA1, similarly to HGPS cells 
(Fig. 3D). Because NAT10 inhibition normalized NUP153 and TPR nuclear accumulation 
and nuclear Ran abundance in HGPS cells (Fig. 1), we the effects of NAT10 inhibition on the 
TNPO1 pathway. Both Remodelin treatment and siRNA-mediated NAT10 depletion restored 
the nuclear-to-cytoplasmic ratio of TNPO1 in HGPS cells so that it was comparable to that of 
control fibroblasts (Fig. 3 A-B). Taken together, these results suggested that the TNPO1 
pathway is affected in both HGPS cells and in cells from aged individuals, leading to defects 
in the nuclear import of TNPO1 and its cargos, including hnRNPA1 and NUP153, thereby 
contributing to downstream defects of the RanGTP gradient. We conclude that NAT10 
inhibition results in global normalisation of TNPO1 subcellular localisation and function in 
HGPS cells, thereby alleviating downstream phenotypes. Although TNPO1 depletion itself 
reduced proliferation of normal retinal pigmented epithelial RPE-1 cells (Fig. S5A), the 
TNPO1 pathway defects observed in HGPS and in ageing cells did not appear to be a mere 
consequence of slower cell growth. Indeed, mimicking reduced cell growth through serum 
starvation of RPE-1 cells and control fibroblasts did not discernibly affect the TNPO1 
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pathway, nor the subcellular localisation of Ran or H3K9me3 (Fig. S5B-D), all of which are 
strongly affected in HGPS cells.  
 
Modulation of microtubule stability by NAT10 inhibition affects the TNPO1 pathway 
We previously observed that HGPS fibroblasts have a more stable microtubule network than 
control cells (21) and that this contributes to HGPS cellular phenotypes. We also showed that 
NAT10 inhibition improved these phenotypes, at least in part by targeting and destabilizing 
microtubules, thus releasing cytoskeletal forces on the nucleus and normalizing nuclear shape 
(21). This is in accord with a pool of NAT10 being associated with the cytoskeleton, as 
observed by subcellular fractionation and immunofluorescence (Fig. S6A-B). To assess 
whether there was a link between accumulation of TNPO1 in the cytoplasm of HGPS cells 
and microtubule stability, we first performed a PLA assay between TNPO1 and a-tubulin. 
Despite similar TNPO1 and a-tubulin staining intensities observed by immunofluorescence 
(Fig. S7A) and similar protein abundance observed by Western blotting (Fig. S7B), the 
interaction between TNPO1 and a-tubulin was significantly greater in HGPS fibroblasts than 
in control fibroblasts, whether measured per cell or per defined area of cytoplasm (Fig. 4A-
B). The reason for measuring the number of PLA spots within a defined area was to account 
for the fact that senescent cells are larger than non-senescent cells, which could have biased 
the results. However, there was a significant increase in the number of PLA spots even within 
a defined area of cytoplasm (Fig. 4B right panel), showing that the increased interaction was 
not a reflection of the increased size of HGPS cells. The interaction between TNPO1 and a-
tubulin was confirmed by immunoprecipitation using extracts of control fibroblasts (Fig. 
S7C). 
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To understand whether the effect of NAT10 inhibition on TNPO1 was associated with 
microtubule stabilization, we treated unaffected and HGPS fibroblasts with the microtubule 
stabilizing or destabilizing agents tubacin or nocodazole, respectively (Fig. 4C). Mimicking 
microtubule stabilization, such as occurs in HGPS cells, by treating control fibroblasts with 
tubacin led to significant defects in both TNPO1 and hnRNPA1 nuclear import (Fig. 4C-D). 
By contrast, destabilizing microtubules in HGPS cells or in cells from unaffected aged 
individuals with nocodazole enhanced TNPO1 nuclear localization and, presumably by 
promoting TNPO1 transport function, increased the nuclear abundance of hnRNPA1 (Fig. 
4C-D and Fig. S8). These results suggested that the TNPO1 import pathway can be altered by 
microtubule stability, and that by modulating this, NAT10 inhibition re-balanced the TNPO1 
nuclear-to-cytoplasm ratio and enhanced the nuclear import of TNPO1 cargo proteins.  
 
Normalisation of HGPS cells by NAT10 inhibition requires TNPO1 
To determine whether the normalization of heterochromatin markers and decreased 
senescence that we previously observed in HGPS cells upon NAT10 inhibition (21) depended 
on TNPO1, we treated control and HGPS fibroblasts with siRNAs to deplete NAT10 alone or 
in combination with NUP153 or TNPO1 depletion. As we observed previously (20), NUP153 
depletion in control cells led to loss of nuclear Ran, probably because it affects the structure 
of nuclear pore complexes that are important for RanGTP gradient formation. However, 
NUP153 depletion did not affect the TNPO1 pathway, as observed by the normal subcellular 
localisation of TNPO1 and its downstream target hnRNPA1 (Fig. S9). Cells impaired in 
nuclear Ran due to TNPO1 depletion (Fig. 5A and Fig. S10) or as observed in HGPS cells 
(Fig. 5B), also displayed significantly reduced abundance of the heterochromatin marker 
H3K9me3 (Fig. 5C). This is in accordance with the chromatin decompaction that we 
observed upon Ran deregulation (Fig. 2B, C) and suggested that TNPO1 depletion was 
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sufficient to cause this phenotype. Furthermore, simultaneous depletion of NUP153 and 
NAT10 in control fibroblasts produced similar H3K9me3 phenotypes compared to NUP153 
depletion alone (Fig. 5A, C), identifying NUP153 as a critical mediator of NAT10-dependent 
cellular rebalancing. Whereas NAT10 depletion alone restored nuclear Ran and H3K9me3 
staining in HGPS cells, this did not happen when NUP153 or TNPO1 was co-depleted with 
NAT10 (Fig. 5B, C). Similarly, although NAT10 depletion strongly decreased the proportion 
of HGPS cells positive for senescence-associated β-galactosidase, this was not the case when 
NUP153 or TNPO1 was co-depleted with NAT10 (Fig. 5D-E). These results indicated that 
the normalization of phenotypes caused by NAT10 depletion in HGPS cells indeed occurred 
through restoration of TNPO1 pathway function. Thus, when TNPO1 or its cargo NUP153 is 
absent, NAT10-dependent phenotypic rescue does not occur. TNPO1 or NUP153 depletion in 
control fibroblasts also promoted senescence, implying that the TNPO1 pathway is important 
for maintaining cellular homeostasis.  
 
TNPO1 is required for NAT10 inhibition-mediated gene expression modulation 
In light of the above observations, we hypothesized that enhancing TNPO1-mediated nuclear 
import in HGPS cells by inhibiting NAT10 might have an impact on gene expression. To test 
this idea, we performed global gene expression analysis on HGPS fibroblasts compared to 
control fibroblasts, both after 8 weeks of DMSO-only or Remodelin treatment (media was 
supplemented with fresh Remodelin every 3 days).  Volcano plots of each individual 
differential expression analysis (Fig. 6A) show log10-adjusted p-values plotted against log2 
fold gene expression changes. Significant genes (based on a fold-change threshold of 2-fold 
up or down and an adjusted p-value threshold of 0.05) are indicated by the red (increased 
expression) and blue (decreased expression) regions of the plots. As expected and as 
previously reported (32,36,42), we observed deregulation of gene expression in HGPS cells 
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compared to control fibroblasts (Fig. 6A left panel and Fig. 6B row 1), with 137 and 221 
genes showing significantly increased or decreased expression, respectively. Notably, chronic 
long-term treatment with Remodelin had very little effect on gene expression in control 
fibroblasts, with only 17 genes exhibiting significantly increased or decreased expression 
(Fig. 6A). In marked contrast, Remodelin had a strong effect on HGPS cells (Fig. 6A), 
modifying the expression of 652 genes (Table S1). Strikingly, these Remodelin-induced gene 
expression changes in HGPS cells were largely reciprocal to the gene expression differences 
between HGPS cells and unaffected cells (Fig. 6B). Thus, long-term Remodelin treatment 
had a strong rebalancing effect on the expression of most genes that are deregulated in HGPS 
cells. 
 
Next, we asked whether the gene expression changes mediated by NAT10 inhibition would 
still occur in the absence of TNPO1. To address this question, we performed a separate 
microarray analysis following short-term depletion of NAT10, TNPO1, or both NAT10 and 
TNPO1 by siRNA. We used NAT10 siRNA instead of Remodelin in this experiment to 
enable rigorous comparison to siRNA-mediated depletion of TNPO1. Due to the shorter 
timeframe of siRNA experiments, we applied a lower threshold (1.5-fold up or down) in this 
analysis, which increased the number of deregulated genes in HGPS cells treated with a 
control siRNA (Fig. 6C) compared to earlier experiments with Remodelin (Fig. 6A). Similar 
to Remodelin treatment, NAT10 depletion modified the expression of more genes in HGPS 
cells than it did in control fibroblasts (Fig. 6C and Table S2) and had a stronger effect than 
Remodelin on control fibroblasts. Indeed, siRNA-mediated NAT10 depletion abolished all 
functions of NAT10, such as its RNA helicase activity and its role in ribosome biogenesis 
(43). Even though we did observe a rebalancing effect on some HGPS deregulated genes 
(Fig. 6D), short-term NAT10 depletion by siRNA treatment did not have comparable effects 
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to Remodelin treatment on global gene expression rebalancing (Fig. 6D). This suggests that 
long-term NAT10 inhibition is required to observe global rebalancing of the HGPS gene 
expression profile.  
 
To assess whether gene expression changes mediated by NAT10 depletion were occurring 
through TNPO1, we compared NAT10 depletion alone with simultaneous depletion of 
NAT10 and TNPO1 (Fig. 7A). We observed that 70% of the genes showing significantly 
increased or decreased expression upon NAT10 depletion alone in control fibroblasts were 
not additionally modified upon simultaneous depletion of TNPO1 (Fig. 7B, Tables S3-4), 
despite similar NAT10 protein knock-down (Fig. 7A). In HGPS cells, this number was 
reduced to 40% (Fig. 7C), likely a result of the deregulation of additional pathways. 
However, because we observed that the TNPO1 pathway was required for the NAT10 
inhibition–mediated phenotypic changes in HGPS cells, we hypothesized that this specific set 
of genes (Fig. 7C) would be mainly responsible for the HGPS cellular rescue. Gene ontology 
analysis of those genes significantly affected by NAT10 depletion only (Table S5) and not by 
simultaneous depletion of NAT10 and TNPO1 in HGPS cells showed an enrichment for 
various cellular components (Fig. 7D), including cell-substrate junctions and focal adhesions, 
extracellular matrix, and endoplasmic reticulum for genes showing decreased expression or 
Golgi and small ribosomal subunits for genes showing increased expression. When we 
plotted this specific set of genes that we refer to as “siNAT10 only” genes on a heatmap (Fig. 
7E), we observed that the expression of about 40% of this specific set of genes was 
rebalanced towards the expression observed in control fibroblasts (Fig. 7E).  
 
Finally, to assess whether the TNPO1 pathway was affected in HGPS, we compared the 
effect of TNPO1 depletion on gene expression profiles in control fibroblasts (Fig. 7F) with 
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gene expression in HGPS fibroblasts treated with a control siRNA compared to control 
fibroblasts treated with a control siRNA (Fig. 7F). This showed that 58% of the genes 
exhibiting significantly increased or decreased expression upon TNPO1 depletion in control 
fibroblasts showed a similar trend in HGPS cells treated with control siRNA (Fig. 7F). 
TNPO1 depletion can be expected to have differential effects compared to a change of 
TNPO1 subcellular localisation as observed in HGPS, where the protein is still expressed but 
is mislocalized (Fig. 7A and Fig. 7F). Moreover, short-term TNPO1 depletion by siRNA 
might not recapitulate the effects of long-term decreased nuclear abundance of TNPO1 
observed in HGPS cells. These results however support our hypothesis that the TNPO1 
pathway is affected in HGPS and that NAT10 inhibition mediates gene expression changes, 
at least in part through TNPO1. Collectively, our results suggest that NAT10 inhibition 
enhances global HGPS cell fitness by restoring TNPO1 function, thus rebalancing nucleo-
cytoplasmic transport, which restores normal chromatin organization and control of gene 
expression and prevents premature entry into senescence.   
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DISCUSSION 
 
TNPO1 dysfunction in HGPS drives nuclear Ran defects 
In this study, we established that the TNPO1 nuclear importer is mislocalized in cells derived 
from patients with HGPS. Furthermore, we found that defective nuclear import of TNPO1 
cargo proteins including NUP153 (24) and hnRNPA1 (27) appeared to contribute to 
downstream phenotypic defects in HGPS cells, including abnormal nuclear pore assembly, 
chromatin disorganisation, gene expression changes, and premature entry into senescence. 
Although previous studies had reported RanGTP gradient defects in cells from HGPS 
patients (9,10), the mechanism behind it was still unclear. Given the known link between 
oxidative stress and nucleocytoplasmic transport (as reviewed in (44)), and because oxidative 
stress is higher in HGPS cells (11), it was thought to be the main cause of decreased nuclear 
Ran abundance in progeria. However, oxidative stress has been shown to affect classical 
importin-mediated nuclear import pathways (45), whereas we found here that the TNPO1 
pathway appeared to be most affected in HGPS. Therefore, based on our findings herein, we 
suggest that depletion of Ran from the nucleus in HGPS cells is a consequence of 
dysfunctional TNPO1, rather than a direct effect of the presence of progerin, oxidative stress, 
or NUP153 deregulation. In addition, by showing that NAT10 inhibition restores TNPO1-
dependent nuclear import by releasing TNPO1 from the cytoplasm of HGPS cells, we have 
provided insights into how NAT10 inhibition, through its effects on microtubule stability, 
ameliorates cellular defects of HGPS cells. As described previously (21), NAT10 inhibition 
does not affect progerin abundance or localisation, suggesting that its effects on HGPS cells 
occur through a progerin-independent pathway.  
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It is still unclear how NAT10 activity might increase during normal and premature ageing. 
However, it has been suggested that NAT10 activity is modulated by auto-acetylation and 
that sirtuin proteins can mediate NAT10 deacetylation (46).  Sirtuin proteins have been 
linked to various age-related pathologies (reviewed in (47)), with their decreased activity 
being associated with senescence. In this context, reactivation of SIRT1 has been shown to 
extend health and lifespan in an HGPS mouse model (48). Therefore, we speculate that 
decreased sirtuin activity as occurs in aging might lead to increased NAT10 acetylation and 
activity, therefore contributing to increased microtubule stability and retention of TNPO1 in 
the cytoplasm. Whether the acetylation of other reported NAT10 substrates such as p53 (49), 
the upstream binding factor (UBF) (50), and rRNA (51) is also affected in HGPS warrants 
investigation.  
 
Microtubule stability modulates nucleocytoplasmic transport 
Based on our findings, we propose a model for how TNPO1-mediated nuclear import affects 
the nucleocytoplasmic RanGTP gradient and how sequestration of TNPO1 in the cytoplasm 
perturbs this process (Fig. 8). 1) Under normal circumstances, TNPO1 binds to specific cargo 
proteins, such as NUP153, in the cytoplasm. 2) The TNPO1-cargo complex is translocated 
into the nucleus through the nuclear pore, which is anchored to microtubules and 
microfilaments in the cytoplasm (52). 3) Once in the nucleus and upon RanGTP binding to 
TNPO1, the NUP153 cargo dissociates from TNPO1 and is incorporated as a component of 
the NPC basket structure, which is responsible for anchoring TPR (18,19), the last 
nucleoporin to be assembled on the NPC (53). The resulting mature NPC is then fully 
functional for nucleocytoplasmic transport and other NPC-dependent roles, such as anchoring 
chromatin. 4) During the progression of HGPS and during ageing of unaffected cells, 
increased microtubule network stability appears to sequester TNPO1 and its cargo proteins in 
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the cytoplasm. 5) As a consequence, TNPO1 cargoes, like NUP153, are not imported 
properly into the nucleus, which prevents NUP153 from being incorporated efficiently into 
NPCs. This in turn affects the nuclear import of Ran, resulting in decreased nuclear Ran 
abundance, as well as defects of TPR anchorage at NPCs. Consequently, during the 
progression of HGPS and upon normal-cell ageing, there is progressive chromatin 
disorganisation and decompaction, global gene expression changes, and premature entry into 
senescence. We speculate that the global dysregulation of gene expression observed in HGPS 
cells is probably a consequence of both a direct effect of abnormal nuclear architecture on 
chromatin organisation and of nucleocytoplasmic transport defects affecting the nuclear 
import of various proteins, including TPR, which directly binds chromatin (39) and 
hnRNPA1, which modulates the activity of transcription factors (28-30). 6) By destabilising 
the microtubule network (21), NAT10 inhibition releases TNPO1 from the cytoplasm in 
HGPS or in cells from unaffected aged individuals, thus enhancing its nuclear translocation 
together with the ensuing nuclear import of its cargos such as NUP153 and hnRNPA1. This 
then substantially normalizes chromatin organisation, Ran-mediated nucleocytoplasmic 
transport, and global transcription patterns. In support of this model, wherein NAT10 
inhibition ameliorates HGPS phenotypes through the TNPO1 pathway, we found that 
Remodelin had little effect on HGPS phenotypes when the cells had been depleted of 
TNPO1.  
 
In addition to helping to explain the mechanistic basis for HGPS cell dysfunction, our study 
highlights how specific components of the nucleocytoplasmic transport machinery are 
affected by a range of factors, in this case cytoskeletal integrity. This correlates with the 
finding that mechanical forces can modulate nuclear pore opening and conformation, thereby 
modifying nucleocytoplasmic transport efficiency (54). Finally, our study underscores the 
20	
potential for NAT10 inhibition as a possible therapeutic strategy for HGPS, and perhaps also 
for certain pathologies associated with aging.   
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MATERIAL AND METHODS 
Cell culture and transfections  
Control skin primary fibroblasts from a young healthy individual (GM03440, 20 years old), 
from two Hutchinson-Gilford progeria syndrome patients (AG11498: 14 years old and 
AG11513: 8 years old), and from four aged individuals (AG11240: 81 years old female, 
AG04059: 96 years old male, AG05248: 87 years old male, AG09602: 92 years old female) 
were purchased from Coriell Cell Repositories and used in passage-matched cells (unless 
indicated otherwise on the figure) between passage numbers 9 and 25. Cells were grown in 
Dulbecco’s modified Eagle medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal 
bovine serum (BioSera), 2mM L-glutamine, 100U per ml penicillin, 100 µg ml-1 
streptomycin. Normal Retinal Pigmented Epithelial Cells (RPE-1) were grown in 
DMEM:F12 (Sigma-Aldrich) supplemented with 10% fetal bovine serum (BioSera), 2mM L-
glutamine, 100U per ml penicillin, 100 µg ml-1 streptomycin. For serum starvation 
experiments, the same medium was used without any fetal bovine serum. The following 
siRNA duplexes were purchased from Life Sciences: NAT10 stealth RNAi: 
GAGCAUGGACCUCUCUGAAUACAUA, and stealth RNAi negative control duplexes. 
TNPO1 siRNAs were from Sigma Aldrich: GCAAAGAUGUACUCGUAAG, 
GUAUAGAGAUGCAGCCUUA, and GUAAAUACCAGCAUAAGAA. Smart pool 
NUP153 and NTF2 siRNA oligonucleotides where purchased from Dharmacon. siRNA 
transfections were carried out using Lipofectamine RNAiMax (Life Sciences), following the 
manufacturer’s instructions. Cells were analysed 48 to 72 h after transfection. U2OS human 
osteosarcoma cells were grown in DMEM supplemented as above. A plasmid encoding the 
TNPO1 inhibitor Myc-MBP-M9M (41) was transfected using Lipofectamine 2000 (Life 
Sciences), following the manufacturer’s instructions. Cells were analysed 24h after 
transfection.  
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Cell proliferation  
Non-transformed human RPE-1 cells were plated at equivalent low densities and transfected 
with control (siCT) or TNPO1 (siTNPO1) siRNA as explained above. Six days later, cells 
were fixed and stained with crystal violet staining solution (0.5% Crystal Violet, 20% 
methanol). 
 
Cell growth inhibition 
RPE-1 cells or control fibroblasts were kept in either normal medium supplemented with 
10% fetal bovine serum (FBS) or in medium without serum to arrest cell proliferation. After 
4 days of serum deprivation, cells were processed for immunofluorescence.  
 
Drug treatments 
Remodelin was synthetized as described previously (21) and added to cell cultures for a final 
concentration of 1 µM for at least 5 days, replacing the medium every 3 days. For 
immunofluorescence assays, Nocodazole and Tubacin were added to the medium for 16h at 
100ng/ml and 10µM, respectively. 
 
Senescence assay 
Senescence was assessed 72h after siRNA transfection using the Senescence β-Galactosidase 
Staining Kit #9860 from Cell Signaling Technology. Blue cells were counted using the Cell 
Counter plugin from Image J. 
 
Immunoblotting 
23	
Total cell extracts were prepared by scraping cells from culture plates in SDS lysis buffer 
(4% SDS, 20% glycerol, and 120 mM Tris-HCl, pH 6.8), boiling for 5 min at 95°C, followed 
by 10 strokes through a 25-gauge needle. Before loading, lysates were diluted with a solution 
of 0.01% bromophenol blue and 200 mM DTT and boiled for 5 min at 95°C. Proteins were 
resolved by SDS-PAGE on 4-12% gradient gels (NUPAGE, Life Sciences) and transferred 
onto nitrocellulose membrane (Protran; Whatman). Secondary antibodies conjugated to 
IRDye 800CW were from LI-COR Biosciences and used at 1:10000. Detection was 
performed with an imager (Odyssey; LI-COR Biosciences). 
 
Subcellular fractionation  
Cells were harvested with trypsin-EDTA and centrifuged at 500xg for 5 min. Cells were 
washed once with 1ml ice-cold PBS and centrifuged at 500xg for 5min. Supernatant was 
removed, and 20µl of packed cell volume was processed for subcellular fractionation using 
the kit for cultured cells from ThermoFisher (Cat number 78840), using the manufacturer’s 
instructions. Subcellular fractions were then processed for immunoblotting as described 
above. Protein compartmentalisation in chromatin and cytoskeletal fractions was assessed by 
detection of the Histone H3 and alpha-Tubulin proteins. 
  
Immunofluorescence  
Cells were washed with PBS and fixed for 20 min with 2% PFA in PBS. Cells were 
permeabilised for 5 min with PBS/0.2% Triton X-100, and blocked with PBS/0.2% Tween 20 
(PBS-T) containing 5% BSA. Coverslips were incubated for 1 h with primary antibodies and 
for 30 min with appropriate secondary antibodies coupled to Alexa Fluor 488, 594 or 647 
fluorophores (Life Technologies, 1:1000), before being incubated with 2µg/ml DAPI. 
Pictures were acquired with a FluoView 1000 confocal microscope (Olympus) using the 
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same laser power for matching images and antibodies. All the immunofluorescence 
experiments were performed at least 3 times independently and the pictures shown in the 
figures are representative images of the 3 experiments. Image analyses were carried out with 
the Volocity software (PerkinElmer) using the following protocol: Find objects (DAPI). 
Subpopulation: Fill holes in objects. Exclude touching edge of image. Exclude objects by 
size: <100µm2. Measure. The fluorescence intensity in each channel was then recorded.  
 
Proximity Ligation Assay (PLA)  
The PLA assays were carried out using the Duolink® In Situ Red Starter Kit Mouse/Rabbit 
(DUO9101, Sigma Aldrich) following manufacturer’s instructions. Image analysis was 
carried out with the Volocity software (PerkinElmer) using the following protocol: Find 
objects (DAPI). Exclude objects >1000µm2 and <20µm2. Fill holes in objects. Exclude 
touching edge of image. Find spots using intensity. Compartmentalize: Divide spots – 
Between nuclei. Select ROI and record the number of PLA spots.  
 
Primary Antibodies 
All of the antibodies used in this study and the concentrations at which they were used for 
immunofluorescence and Western blotting are summarized in Table S6. 
 
Micrococcal nuclease digestion sensitivity assay 
Because this assay requires a lot of cells, we could not perform it with HGPS cells and thus 
used human osteosarcoma U2OS cells instead. 1x106 cells were trypsinized, harvested, and 
washed once with 1ml of 1xRSB buffer (10 mM Tris, pH 7.6, 15 mM NaCl, and 1.5 mM 
MgCl2). After centrifugation (300 x g), the cell pellet was resuspended in 1 ml of 1x RSB 
buffer with 1% Triton-X 100 and homogenized by five strokes with a loose-fitting glass 
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pestle to release nuclei. Nuclei were collected by centrifugation (13, 000 x g) and washed 
twice with 1 ml of buffer A (15 mM Tris, pH 7.5, 15 mM NaCl, 60 mM KCl, 0.34 M sucrose, 
0.5 mM spermidine, 0.15 mM spermine, 0.25 mM PMSF, and 0.1% b-mercaptoethanol). 
Nuclei were resuspended in Buffer A and aliquoted into 100 µl aliquots. 1.2µl of 0.1 M 
CaCl2 was added to each aliquot and nuclei were digested by addition of 0.25 µl of 200 U/ml 
MNase (Sigma-Aldrich) and incubated at 30°C. Each aliquot was put back on ice at different 
time points and digestion was immediately stopped by addition of 3µl EDTA. DNA was 
purified using the Qiagen PCR purification kit and 1500 ng of DNA was analysed on a 1.5% 
agarose gel. Digestion profiles were analysed using ImageJ and values were adjusted relative 
to the global intensity of each lane to compensate for DNA loading variations.  
 
Microarray analysis 
Long-term Remodelin treatment for microarray experiments was performed by keeping and 
passaging cells in medium containing 1 µM Remodelin or DMSO only for 12 population 
doublings. Three independent biological replicates were used for each condition. RNA 
extracted from cells was purified using Direct-zol RNA MiniPrep kit (Zymo Research, cat. 
no. R2072) and treated with DNaseI (Zymo), according to manufacturers’ instructions. RNA 
quality was assessed using the Tapestation (Agilent Technologies) and Qubit 
(Invitrogen). Quality analysis of total RNA, hybridisation and data capture was performed at 
the Cambridge Genomic Services. Illumina HumanHT-12 v4 beadchips were used for gene 
expression screening. Results were analysed using the Lumi (55) Bioconductor package in R. 
Probe-level data were combined to give gene-level data by taking the mean of all probes for a 
single gene. Differentially expressed genes were identified in each cell line using limma (56), 
using a 2-way factorial design with disease state as the first factor (HGPS vs control 
fibroblasts) and treatment as the second factor (Remodelin vs DMSO, or 
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siNAT10/siTNPO1/both vs siCT). Differentially expressed genes were calculated by 
performing pairwise comparisons between the four groups (Treated Normal, Untreated 
Normal, Treated HGPS, Untreated HGPS) for each treatment. All resulting p-values were 
corrected for multiple testing by using the Benjamini and Hochberg False Discovery Rate 
correction (52). Genes were defined as showing significantly altered expression if they 
showed a fold change greater than some threshold value (2-fold up or down for Remodelin, 
1.5-fold up or down for siRNA) compared to control, with an adjusted p-value lower than 
0.05.   
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SUPPLEMENTARY MATERIALS 
Fig. S1. NAT10 inhibition rescues impaired TPR nuclear localisation in cells from aged 
individuals. 
Fig. S2. Nuclear import is affected in HGPS. 
Fig. S3. TNPO1-dependent protein cargos are affected in HGPS cells. 
Fig. S4. NAT10 nuclear import does not depend on TNPO1. 
Fig. S5. Cell proliferation inhibition does not affect the Transportin-1 pathway. 
Fig. S6. NAT10 localises both in the nucleus and in the cytoskeleton. 
Fig. S7. TNPO1 accumulates at the microtubule network of HGPS cells. 
Fig. S8. Microtubule destabilization rescues TNPO1 pathway defects in HGPS cells and in 
cells from aged individuals. 
Fig. S9. NUP153 depletion does not affect the Transportin-1 pathway. 
Fig. S10. Efficiency of protein depletions. 
Table S1. List of genes modified by Remodelin treatment. 
Table S2. List of genes modified by NAT10 depletion. 
Table S3. List of genes modified by depletion of TNPO1 and NAT10. 
Table S4. List of genes modified by TNPO1 depletion. 
Table S5. Gene ontology analysis of “siNAT10-only” genes. 
Table S6. Primary antibodies. 
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FIGURES 
 
39	
Fig. 1 NAT10 inhibition rescues the reduced nucleocytoplasmic transport in progeric 
and aged cells. (A) Representative immunofluorescence images showing subcellular 
localisation of Ran in skin fibroblasts from a 20-year-old healthy male (Control fibro), aged 
individuals (AG11240, a 81-year-old female; AG04059, a 96-year-old male; AG05248, a 87-
year old-male; AG09602, a 92-year-old female), and an 8-year-old HGPS patient (HGPS 
11513). N = 3 independent experiments. (B) Representative Western blot showing the 
abundance of the indicated proteins in extracts of fibroblasts from young, aged, and HGPS 
individuals. N = 3 independent experiments. (C) Representative immunofluorescence images 
showing nuclear Ran and TPR in HGPS cells as compared to control cells. (D) Quantification 
of TPR nuclear intensity in the indicated cells. N = 3 independent experiments, n>100 nuclei 
per experiment for each cell type. *p=0.016 (Mann Whitney test). Error bars indicate s.e.m. 
(E) Representative immunofluorescence images showing localization of NUP153 and TPR in 
control and HGPS fibroblasts in the absence (untreated) or presence of the NAT10 inhibitor 
Remodelin. (F) Quantification of NUP153 and TPR nuclear intensity from experiments in 
(E). N = 3 independent experiments, n>70 nuclei per experiment for each cell type. P values 
from left to right: *p=0.0111, ***p=0.0002, *p=0.0163, ***p=0.0007 (Mann Whitney test). 
Error bars indicate s.e.m. (G) Proximity ligation assay (PLA) showing the interaction of TPR 
and NUP153 in control and HGPS fibroblasts in the absence (untreated) or presence of the 
NAT10 inhibitor Remodelin. Results of the PLA were quantified as the mean number of dots 
per nucleus. N = 3 independent experiments, n>50 nuclei per experiment for each cell type. 
(H) and (I) Ran nuclear localisation in control and HGPS fibroblasts upon siRNA-mediated 
depletion of NTF2 (siNTF2) or NAT10 (siNAT10) or upon NAT10 inhibition (Remodelin). 
siCT, control siRNA. N = 3 independent experiments, n>70 nuclei per experiment for each 
cell type. P values from left to right: **p=0.0043, ****p<0.0001, ns: non significant, 
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****p<0.0001, **p=0.0029 (Mann Whitney test). Error bars indicate s.e.m. All scale bars, 
50µm. 
 
 
Fig. 2 Disruption of Ran induces chromatin relaxation and senescence. (A and B) 
Analysis of chromatin relaxation by MNase assay in U2OS cells upon siRNA-mediated TPR 
depletion (siTPR) or disruption of Ran nuclear import by NTF2 depletion (siNTF2). siCT, 
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control siRNA. Scale bar, 30µm. Digested chromatin was analysed on an agarose gel and 
quantified using ImageJ. The graph is a representative figure of three independent 
experiments and represents the relative bands intensity (y axis) of the digested nucleosomes 
that migrate further from the well (x axis) because the chromatin is more relaxed, and thus 
more accessible to the MNase enzyme. (C) Representative immunofluorescence images 
showing H3K9me3 staining in young fibroblasts at passage number 19 (Control Fibro P19), 
old fibroblasts at passage number 61 (Control Fibro P61), and HGPS cells at passage 19 
(HGPS 11513 P19) upon transfection with siCT or siNTF2 to disrupt the RanGTP gradient. 
Scale bar, 50µm.  (D) Quantification of H3K9me3 nuclear intensity from (C). N = 2 
independent experiments, n>50 nuclei per experiment for each cell type. P values from left to 
right: *p=0.0159, *p=0.014 (Mann Whitney test). Error bars indicate s.e.m. (E) Senescence-
associated β-galactosidase staining (blue cells) upon transfection with siCT or siNTF2 siRNA 
in control (Control fibro) and HGPS (HGPS 11513) fibroblasts at the indicated passage 
number (P). Scale bar, 50µm. (F) Quantification of blue cells from experiments in (C). N = 3 
independent experiments, n>200 nuclei per experiment for each cell type.  P values from left 
to right: ***p=0.0003, ***p=0.0002 (Mann-Whitney test). Error bars indicate s.e.m. 
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Fig. 3 The TNPO1 pathway is defective in HGPS cells and rescued by NAT10 inhibition. 
(A) Representative immunofluorescence images showing the subcellular localization of 
TNPO1 and its cargo hnRNPA1 in control and HGPS fibroblasts in the absence (untreated) 
or presence of the NAT10 inhibitor Remodelin. (B) Higher magnification images from panel 
(A) showing TNPO1 nuclear and cytoplasmic subcellular localisation, quantified below as 
nuclear-to-cytoplasmic ratio (N:C). Nuclei are outlined with white dotted lines. Box plots 
represent median (line), 10-90 percentiles (whiskers) and outliers (dots). N = 3 independent 
experiments,  n>50 nuclei per experiment for each cell type. P values from left to right: 
****p<0.0001, ***p=0.0003, ****p<0.0001, ns: non significant. (Mann Whitney test). Error 
bars indicate s.e.m. (C). Representative immunofluorescence images showing TNPO1 
subcellular localisation in fibroblasts from other HGPS patients (HGPS 11498) and in cells 
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from healthy aged individuals (AG11240 and AG059). N = 3 independent experiments. (D) 
Western blot showing total TNPO1 and hnRNPA1 abundance in the indicated cells. N = 3 
independent experiments. All scale bars, 50µm. 
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Fig. 4 Microtubule reorganisation modulates TNPO1 localisation and function. (A) 
Representative immunofluorescence images from proximity ligation assays (PLA) in control 
and HGPS fibroblasts using antibodies recognizing TNPO1 and a-tubulin. Each dot 
represents an interaction between one molecule of TNPO1 and one molecule of alpha-
tubulin. Scale bar, 20µm. (B) Quantification of the PLA assays shown in (A), representing 
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both the total number of dots per cell (left) or the average number of spots in a defined area 
of cytoplasm (right). N = 3 independent experiments, n>46 nuclei per experiment for each 
cell type. P values: ***p=0.0005, ***p=0.0003 (Mann Whitney test). Error bars represent 
s.e.m. (C) Representative immunofluorescence images showing the effect of compounds that 
destabilize (nocodazole) or stabilize (tubacin) the microtubule network on the nuclear 
localization of TNPO1 and its cargo hnRNPA1. Scale bar, 50µm. (D) Quantification of the 
TNPO1 nuclear-to-cytoplasmic ratio (N:C) and of hnRNPA1 nuclear intensity. Box plots 
represent median (line), 10-90 percentiles (whiskers) and outliers (dots). N = 3 independent 
experiments, n>50 nuclei per experiment for each cell type. Top graph p values from left to 
right: **p=0.0011, ***p=0.0002, ***p=0.0002, ns: non significant. Bottom graph p values 
from left to right: ***p=0.0002, ***p=0.0001, ***p=0.0001, **p=0.0023, ns: non significant 
(Mann Whitney test). Error bars represent s.e.m. 
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Fig. 5 TNPO1 is required for cellular normalisation mediated by NAT10 inhibition. (A 
and B) Representative immunofluorescence images showing Ran and H3K9me3 staining in 
control (A) or HGPS (B) fibroblasts after transfection with the indicated siRNA. (See Fig. 
S10 for protein knockdown efficiency). N = 3 independent experiments. Scale bar, 50µm. (C) 
Quantification of H3K9me3 and Ran nuclear intensity from the cells in (A) and (B). N = 3 
independent experiments, n>150 cells per experiment for each cell type. P values from left to 
right: H3K9me3 in control fibroblasts: *p=0.0195, **p=0.0087, *p=0.0315, *p=0.0197, 
**p=0.0064. H3K9me3 in HGPS fibroblasts: **p=0.0097, *p=0.03, *p=0.0393. Ran in 
control fibroblasts: *p=0.025, **p=0.0075, *p=0.0443, *p=0.011, *p=0.015. Ran in HGPS 
fibroblasts: *p=0.0342, *p=0.0407, *p=0.0368 (Unpaired t test). Error bars indicate s.e.m. 
(D) Senescence-associated β-galactosidase (SA-β-Gal) staining in HGPS fibroblasts that had 
been treated with the indicated siRNAs. (E) Quantification of SA-β-Gal staining in (D). N = 
3 independent experiments, n>200 cells per experiment for each cell type. P values from left 
to right: *p=0.0107, *p=0.049, ***p=0.0001, ****p<0.0001, ns: non significant (Unpaired t 
test). Error bars indicate s.e.m. 
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Fig. 6 Effects of NAT10 inhibition or depletion on gene expression. (A) Volcano plots 
from the microarray analysis showing the number of genes with decreased (blue) or increased 
(red) expression in HGPS fibroblasts compared to control fibroblasts, in control fibroblasts 
treated with Remodelin, and in HGPS fibroblasts treated with Remodelin. N = 3 independent 
experiments. The log10 of the adjusted p-value is used such that the more significant a gene 
in gene expression is, the higher it will appear on the y-axis. The log2 of the fold change is 
used such that genes with increased (red) or decreased (blue) expression have equal 
weighting in the plot. Genes were classified as showing gene expression changes if they 
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showed a change of 2-fold (up or down) or greater with an adjusted p value less than or equal 
to 0.05. For both control and HGPS fibroblasts, Remodelin was used as a chronic treatment 
for eight weeks (middle and right panels). (B) Heat maps of genes with significantly altered 
expression from (A) showing the effect of Remodelin treatment on gene expression in HGPS 
cells. (C) Volcano plots from the microarray analysis showing the number of genes for which 
expression was decreased (blue) or increased (red) by 1.5-fold or greater under the indicated 
conditions. siRNA-mediated NAT10 depletion (siNAT10) and control siRNA treatment 
(siCT) was transient (5 days). N = 3 independent experiments. (D) Heat maps of genes 
presented with significantly altered expression from (C) showing the effect of NAT10 
depletion on gene expression in HGPS cells.  
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Fig. 7 NAT10 modulates gene expression through TNPO1. (A) Representative Western 
blotting analysis showing the efficiency of siRNA-mediated depletion of NAT10 (siNAT10) 
and TNPO1 (siTNPO1). N = 2 independent experiments. (B and C) Venn diagrams generated 
from the microarray analysis showing the overlap between genes with significantly increased 
or decreased expression upon NAT10 depletion alone or together with TNPO1 depletion 
(siNAT10+siTNPO1) in control (B) and HGPS (C) fibroblasts. (D) Gene ontology analysis 
51	
showing cellular component (CC) terms enrichment from genes with significantly decreased 
(blue) or increased (red) expression only upon NAT10 depletion in HGPS cells.  (E) Heat 
maps of siNAT10-specific genes presented in (C) and (D), showing the gene expression 
changes for genes modified by siNAT10 only (compared to siCT) in HGPS cells (row 1) and 
their expression in HGPS cells compared to control fibroblasts (row 2).  (F) Heat maps of 
genes with expression significantly modified by TNPO1 depletion in control fibroblasts (row 
1), and their expression in HGPS cells compared to control fibroblasts (row 2). TNPO1 is 
indicated by an asterisk. All analyses were performed using three biological replicates. 
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Fig. 8 Model for how NAT10 inhibition rescues HGPS phenotypes. 1) In control cells, 
TNPO1 binds to its cargo proteins, such as NUP153, in the cytoplasm. 2) The TNPO1-cargo 
complex translocates into the nucleus through the nuclear pore. 3) Once in the nucleus and 
upon RanGTP binding to TNPO1, the NUP153 cargo dissociates from TNPO1 and is 
incorporated into the nuclear pore complex (NPC) and recruits TPR to the NPC. Mature, 
fully functional NPCs mediate nucleocytoplasmic transport and other roles, such as 
anchoring chromatin to the nuclear envelope through TPR. 4) In HGPS and aging, increased 
microtubule network stability sequesters TNPO1 in the cytoplasm. 5) TNPO1 cargos such as 
NUP153 are not properly imported into the nucleus. The absence of NUP153 results in 
decreased nuclear Ran abundance and defects in TPR anchorage at NPCs. This leads to 
chromatin disorganisation, global gene expression changes, and premature entry into 
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senescence. 6) By destabilising the microtubule network, NAT10 inhibition releases TNPO1 
from the cytoplasm, enhancing its nuclear translocation together with nuclear import of its 
cargos such as NUP153 and hnRNPA1. This then substantially normalizes chromatin 
organisation, RanGTP mediated nucleocytoplasmic transport, and global transcription 
patterns. 
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Fig. S1. TPR nuclear localisation is impaired in cells from aged individuals and 
normalised by NAT10 inhibition. (A) Representative immunofluorescence images from 
three independent experiments showing nuclear localization of TPR in the indicated cells in 
the absence (top) or presence (bottom) of Remodelin. Scale bar: 50µm. (B) Quantification 
of TPR nuclear intensity from three independent experiments as shown in A (Unpaired t 
test, error bars represent s.e.m. P values from left to right: *p=0.0462, **p=0.0086, 
*p=0.0485, *p=0.024, *p=0.049). 
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Fig. S2. Nuclear import is affected in HGPS. (A) Representative immunofluorescence 
images (left) and quantification (right) of NUP153 (green) and TPR (red) staining from 
three independent experiments in control fibroblasts or fibroblasts from HGPS patient 
11498 (Unpaired t test, P values from left to right: *p=0.0354, *p=0.023) Error bars 
represent s.e.m. (B) Representative immunofluorescence images (left) and quantification 
(right) of Ran from three independent experiments in control fibroblasts or fibroblasts from 
HGPS patient 11498, in untreated cells or upon NAT10 inhibition by Remodelin (Unpaired 
t test, P values from left to right: **p=0.0092, **p=00.43). Error bars represent s.e.m. Scale 
bars: 50µm. 
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Fig. S3. TNPO1 dependent protein cargos are affected in HGPS cells. (A) 
Representative immunofluorescence images from three independent experiments showing 
the subcellular localisation of the NTF2 protein responsible for nuclear import of Ran. Scale 
bar: 50µm. (B) Representative immunofluorescence images from three independent 
experiments showing nuclear staining intensity of TNPO1 cargos including NUP153 and 
the Ewing sarcoma protein EWS in HGPS cells compared to controls. Scale bar: 50µm. (C) 
Quantification of EWS nuclear intensity in the indicated conditions (Unpaired t test from 
three independent experiments, error bars represent s.e.m. P values from left to right: 
**p=0.0016, **p=0.0031).  
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Fig. S4. NAT10 nuclear import is not dependent on TNPO1. (A) Representative 
immunofluorescence images from thee independent experiments showing NAT10 (green) 
and Ran (red) staining in both control and HGPS fibroblasts. Scale bar: 50µm. (B) Human 
osteosarcoma U2OS cells were transfected with the plasmid encoding the TNPO1 inhibitor 
Myc-MBP-M9M (40) (red) to assess the effects on NAT10 nuclear localization (green). 
Scale bar: 20µm. 
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Fig. S5. Cell proliferation inhibition does not affect the Transportin-1 pathway. (A) 
Crystal violet staining of non-transformed human RPE-1 cells transfected with control 
(siCT) or TNPO1 siRNA (siTNPO1). Representative wells from three independent 
experiments are shown. (B) and (C) RPE-1 cells were either kept in normal or in medium 
without serum to arrest cell proliferation. Representative immunofluorescence images from 
three independent experiments showing staining of TNPO1 and its downstream cargo 
hnRNPA1 (B) as well as Ran and the heterochromatin marker H3K9me3 (C). (D) Control 
fibroblasts were either kept in normal or in medium without serum to arrest cell proliferation. 
Representative immunofluorescence images from two independent experiments showing 
staining of TNPO1 and its downstream cargo hnRNPA1. Scale bars: 30µm. 
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Fig. S6. NAT10 localises both in the nucleus and in the cytoskeleton. (A) Representative 
western blotting from two independent subcellular fractionations showing the abundance of 
the indicated proteins in the chromatin and cytoskeletal fractions of control fibroblasts and 
HGPS cells in the absence (non treated, NT) or presence of Remodelin. (B) Representative 
immunofluorescence images from three independent experiments showing the subcellular 
localisation of NAT10 upon low (middle image) or high exposure (right image). Scale bar: 
10µm. 
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Fig. S7. TNPO1 accumulates at the microtubule network of HGPS cells. (A)  
Representative immunofluorescence images from three independent experiments showing 
the signal coming from the anti-TNPO1 (green) and anti-tubulin (red) antibodies used in the 
PLA assay. Scale bars: 50µm. (B) Representative Western blotting from three independent 
experiments showing the global abundance of the indicated proteins in control vs HGPS 
cells. (C) Immunoprecipitation of TNPO1 in control fibroblasts. 
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Fig. S8. TNPO1 pathway is defective in HGPS cells and in cells from aged individuals, 
and this is rescued by microtubule destabilization. Representative immunofluorescence 
images (left) and quantification (right) from three independent experiments showing nuclear 
staining intensity of TNPO1 (red) and hnRNPA1 (green) in HGPS (HGPS11498) and in 
cells from aged individual (AG04059) treated with the indicated molecules. Scale bar: 50µm. 
(Unpaired t test, P values from left to right: ***p=0.0001, **p=0.0069, **p=0.0081, 
*p=0.0128, *p=0.0420, *p=0.0253. Error bars represent s.e.m.). 
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Fig. S9. NUP153 depletion does not affect the Transportin-1 pathway. Control 
Fibroblasts were transfected with the indicated siRNA before being stained for hnRNPA1 
(green) and TNPO1 (red). Representative immunofluorescence images (left) from two 
independent experiments showing the effects of TNPO1 (siTNPO1) or NUP153 depletion 
(siNUP153) on the nuclear staining intensity of hnRNPA1. Scale bar: 50µm. Right: 
Quantification of hnRNPA1 nuclear intensity from two independent experiments in the 
indicated siRNA (Unpaired t test, P value: ***p=0.0004. Error bars represent s.e.m.).  
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Fig. S10. Efficiency of protein depletions. The efficiency of the indicated siRNA was 
assessed by staining for the corresponding proteins. Representatives immunofluorescence 
images in control fibroblasts from three independent experiments are shown. Scale bar: 
50µm. 
 
 
 
After you've completed revising the SM legends, make sure the titles for each figure listed 
here match the titles in the SM list that immediately follows the Materials & Methods in the 
main text. 
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Supplementary Tables 
 
 
Table S1: List of genes modified by Remodelin treatment. 
This table is provided as a separate Excel file and lists the genes modified by Remodelin in 
control and HGPS fibroblasts.  
 
Table S2: List of genes modified by NAT10 depletion. 
This table is provided as a separate Excel file and lists the genes modified upon NAT10 
depletion in control and HGPS fibroblasts.  
 
Table S3: List of genes modified by TNPO1+NAT10 depletion. 
This table is provided as a separate Excel file and lists the genes modified upon NAT10 and 
TNPO1 depletion in control and HGPS fibroblasts.  
 
Table S4: List of genes modified by TNPO1 depletion. 
This table is provided as a separate Excel file and lists the genes modified upon TNPO1 
depletion in control and HGPS fibroblasts.  
 
Table S5: Gene ontology analysis of “siNAT10 only” genes. 
This table is provided as a separate Excel file and lists the genes modified only upon NAT10 
depletion and not upon co-depletion with TNPO1 in control and HGPS fibroblasts.  
 
Table S6. Primary antibodies used in this study. 
Primary antibodies were used at the indicated concentrations for Western blotting (WB) 
and immunofluorescence (IF). 
 
Antibody Cat number Company Dilution WB Dilution IF 
α-tubulin  T9026 Sigma Aldrich 1/500 1/500 
Histone H3 ab1791 Abcam 1/1000 N/A 
H3K9me3 ab8898 Abcam 1/2000 1/1000 
TPR ab58344 Abcam 1/200 1/100 
TNPO1 ab10303 Abcam 1/200 1/200 
Lamin A/C  sc-6215 Santa Cruz 1/400 1/200 
NAT10 13365-1-AP ProteinTech 1/500 1/500 
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hnRNPA1 4296 Cell Signaling 1/100 1/50 
Myc 2276 Cell Signaling N/A 1/5000 
NUP153 A301-788A Bethyl 1/200 1/100 
NUP153 MMS-102P Covance N/A 1/200 
Ran 610341 BD Biosciences 1/500 1/200 
 
